CTI Life Sciences Fund L.P.

Profound Medical develops the MRI-guided TULSA Procedure (TULSA-PRO), an incision-free transurethral ultrasound ablation system for treating prostate tissue in men with conditions such as localized prostate cancer.

BiotechHealthtechMedical DevicesMississauga

Arun Menawat(Executive Officer, Director)Rashed Dewan(Executive Officer)

BoardJean-Francois Pariseau(Director)Damian Lamb(Director)William Curran(Director)Samira Sakhia(Director)

Co-investorsFACIT (Fight Against Cancer Innovation Trust)Genesys Capital

Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques.

BiotechHealthtech

Grant Pickering(Founder)in

Co-investorsBioRock VenturesForesite CapitalFrazier Life SciencesLongitude CapitalRA Capital

Oligon Therapeutics develops RNA-based multi-targeting drugs using its SeekR platform, which combines RNA aptamer oligo-binders with siRNA silencers into a single self-delivering molecule for precise targeting of specific cell types, including T-cells and cancer cells.

AI & Machine LearningBiotech

Thryv Therapeutics is a clinical-stage biotech developing precision-medicine treatments for genetic arrhythmia syndromes and acquired cardiometabolic diseases using selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1).

BiotechDigital HealthMedical Devices

Paul F. Truex(Chairman of the Board & Chief Executive Officer)Debra Odink(President & Chief Development Officer)Amy Sehnert(Chief Medical Officer)Matt Killeen(Chief Business Officer)

BoardSaumya Das(Chief Scientific Advisor)

Co-investorsLumira VenturesadMare BioInnovationsAmzak HealthFonds de solidarité FTQ

AbilityPharma is a biopharmaceutical company developing first-in-class drug candidates for cancer, using autophagy as a therapeutic strategy to selectively induce cell death in cancer cells.

BiotechHealthtech

Co-investorsCapital Cell

Clinical-stage biotherapeutics company developing mTORC1-specific inhibitors.

Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism.

BiotechBerkeley, US

Allison J. Hulme(CEO & President)John Kincaid(Chief Scientific Officer)Davis Ryman(Executive Officer)Micah Zajic(Executive Officer)Ian Massey(Executive Officer)Stelios Tzannis(Executive Officer, Director)

Co-investorsCoastCapFJ LabsSofinnova VenturesvenBio PartnersvenBio Global Strategic

Co-investorsAndera PartnersEQT Life SciencesKurma PartnersLSP (Life Sciences Partners)Sofinnova Partners

Apollo is a venture capital firm that invests in life-science and biotechnology startups, combining entrepreneurial expertise with deep scientific knowledge to support early-stage companies in drug development and personalized medicine.

BiotechDeep TechHealthtechLongevity

Nils Regge(Co-Founder & General Partner)in

Co-investorsBLN CapitalCoastCapFJ LabsKfW CapitalTruVenturo GmbHForesite Capital+3 more

Precision cardiology company built around a Phase 3-ready asset from the Montreal Heart Institute.

Domain Therapeutics develops drug discovery and development therapies that target GPCRs to modulate the immune system, focusing on immuno-oncology and inflammatory diseases.

BiotechDigital Health

Co-investors3B Future Health Fund

enGene is a genetic medicine company developing drug therapies across oncology, urology, and other therapeutic areas, with a focus on patient outcomes.

BiotechMedical Devices

Co-investorsLumira Ventures

Epitopea develops off-the-shelf cancer vaccines targeting aberrantly expressed tumor-specific antigens using its proprietary CryptoMap platform.

AI & Machine LearningBiotechHealthtechMontreal, CA

Claude PerreaultPierre Thibault

Co-investorsAdvent Life SciencesCambridge Innovation CapitaladMare BioInnovationsFonds de solidarité FTQ

Find Therapeutics develops therapies that precision-target membrane receptors to treat demyelinating diseases.

Biotech

Developing therapies for congenital disorders of glycosylation combining replacement therapies with intracellular delivery vehicles.

BiotechSan Francisco, US

Agnes Rafalko(Executive Officer, Director)

BoardPeter C.M. McWilliams(Director)Giacomo Chiesi(Director)Christopher Starr(Director)

Co-investorsAdvent Life SciencesChiesi VenturesRemiges Ventures, Inc.RiverVest Venture PartnersSanderling VenturesSanofi Ventures

BiotechDartmouth

James Hall(Director)Julia P. Gregory(Director)Wayne Pisano(Director)Markus Warmuth(Director)Andrew Sheldon(Director)Pierre Labbe(Executive Officer)

Platform producing potential best-in-class assets against GPCR targets with strong pre-clinical data.

Co-investorsYaletown Partners

Phenomic AI is a biotech company developing therapies for solid tumors using a machine-learning-powered transcriptomics platform that analyzes single-cell RNA data to identify drug targets and understand tumor biology.

AI & Machine LearningBiotechDeep TechToronto, CA

Sam Cooper(Co-founder & CTO)Oren Kraus(Co-founder)

Co-investorsCantos VenturesAV8 VenturesGarage CapitalHemi Ventures, LlcToronto Innovation Acceleration PartnersHike Ventures+1 more

MRI-guided ablation improving survival outcomes with a less invasive approach than traditional methods.

A URL shortcut operated by Google that directs users to official Google products and services.

Co-investorsFirst Bight VenturesSwanlaab Venture FactoryAbstract VenturesGeneral CatalystUnion Square Ventures (USV)Y Combinator

First-in-class treatment for the rare pediatric cardiology disease Long QT Syndrome, with strong Phase 2a efficacy.

Co-investorsPfizer Venture InvestmentsSofinnova Partners

Hierotope platform for precision biologics; acquired by Otsuka.

Co-investorsCycad Group LLCLux CapitalMRL Ventures Fund

BiotechWaltham, US

Garry Nicholson(Executive Officer, Director)Edward Freedman(Executive Officer)Rakesh Jain(Director)

BoardRobert Langer(Director)David Mott(Director)Alan Crane(Director)

Co-investorsPolaris Partners